<DOC>
	<DOCNO>NCT00576589</DOCNO>
	<brief_summary>The study design ass whether repeated dose CE-326,597 cause patient asymptomatic gallstone ( detect screen abdominal ultrasound ) become symptomatic . In addition , study characterize pharmacokinetics CE-326,597 .</brief_summary>
	<brief_title>Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones</brief_title>
	<detailed_description />
	<mesh_term>Cholelithiasis</mesh_term>
	<criteria>Body Mass Index 3040 kg/m2 , inclusive Evidence asymptomatic cholelithiasis screen abdominal ultrasound Patients unstable medical condition , diabetes , stroke , heart attack . Females childbearing potential may pregnant breast feeding . Patients inflammed gallbladder , evidence stone bile duct screen abdominal ultrasound , history symptom indicate active gallbladder disease gallbladder removal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Safety patient Asymptomatic cholelithiasis/gallstones .</keyword>
</DOC>